Ajanta Pharma Q1FY24 Results: Consolidated PAT of Rs. 208.12 Cr

Ajanta Pharma Q1FY24 Results: Consolidated PAT of Rs. 208.12 Cr

Ajanta Pharma Q1 results show revenue up from 918.67 crores to 1,052.79 crores, a 14.60% increase in growth. EPS rise from ₹9.54 to ₹16.53, up by 73.27%.

First, Let’s Begin with Quarter-on-Quarter Basis:

Ajanta Pharma shared its Q1 results on Thursday. They earned 1,052.79 crores in revenue this quarter, but that’s more than the 918.67 crores they made last quarter. The company’s growth increased by 14.60 percent when comparing the two quarters.

In terms of profits, the company’s PAT (Profit After Tax) for this quarter was 208.12 crores, up from 122.25 crores in the previous quarter. Their quarter-to-quarter growth increased by 70.24 percent.

The company’s EPS (Earnings Per Share) this quarter is ₹16.53, which is an increase of 73.27% from the ₹9.54 EPS in the previous quarter.

Now, Let’s Analyze the Results on a Year-over-Year Basis:

The company made a total revenue of 1,052.79 crores this year (2023), which is 7.02 percent higher than last year’s total revenue of 983.69 crores.

This year’s PAT (Profit After Tax) is 208.12 crores, which is also 19.18% higher than last year’s PAT of 174.62 crores.

The EPS (Earnings Per Share) for this year is ₹16.53, which is 21.28% more than the EPS of ₹13.63 earned last year.

Also Read: Bajaj Holdings Q1FY24 Results: Consolidated PAT of Rs. 1,415.5 Cr

Ajanta Pharma Share Dividend Announcement / Record Date:

The record date for the dividend has not arrived yet.

About Ajanta Pharma:

Ajanta Pharma Limited, commonly referred to as APL, is an Indian multinational company that is involved in the development, manufacturing, and marketing of pharmaceutical formulations. The company has a widespread presence in India, the United States, and approximately 30 other countries across Africa, South East Asia, West Asia, and the CIS region.

Download the Full PDF of Ajanta Pharma Q1 Results: Click Here

For more of the Latest News, Click Here

Leave a Reply

Your email address will not be published. Required fields are marked *